Unbelieve resource for providers and fellows! Oncology Brothers Good discussion w/ the best in the country! @URHemeOncFellows UF Hematology/Oncology Fellowship

Dr. Fumiko Ladd Chino, MD discusses financial toxicity in cancer care at The National Academies of Sciences

When care is unaffordable …

ADAURA; look at NEJM supplementary ; 7% 5y landmark advantage for those who got adjuvant chemo. My view will be to recommend adjuvant chemo before adjuvant osimertinib #ASCO23 #LCSM

As biomarkers become more utilized in a variety of cancers, let's highlight current biomarker patient groups. They have a wealth of lived experience. #ASCO23 #LCSM

#ASCO23 Lung rapid abstracts

Clinically-relevant study 🇯🇵 of elderly pts treated with 1L ICI, ICI-chemo or chemo alone (NEJ057):

- mPFS + OS similar with ICI mono or ICI-chemo
- similar benefit in PDL1 >1% & 1-49% propensity-matched groups & all comers

@asco @oncoalert #LCSM

#ASCO2023 Oral Session: TROPION-Lung02: Dato-DXd + pembr) with or without platinum CT Dato-DXd +
pembro Pt-CT demonstrated tolerable safety with notable 1L activity (RR 50% for doublet and 57% for triplet.
Fundación Jiménez Díaz UAM Autónoma Madrid OncoAlert #LCSM Cáncer de Pulmón

KN-789, chemo/pembro v chemo/placebo: signif benefit in PFS, non-signif trend in OS favoring pembro arm. Though this will likely lead to chemo as clearly favored next Rx in acquired resistance, OS is more favorable in those w/PD-L1+.
Wonder what anti-VEGF would add #ASCO23 #LCSM

AVM: KontRASt-01
JDQ443 novel KRAS G12c. inhibitor
Preliminary ORR 57.1% at dose expansion dose
Toxicity profile as expected, ongoing studies with ICIs and other combinations in 1L and 2L+ are ongoing and will reveal it's role among the other KRAS G12c inhibitors
#LCSM #ASCO23

#ASCO23 A9002 (Wang): EGFR exon 20 TKI sunvozertinib appears to be quantum leap over current options for this target, w/ORR 60.8%, active vs. broad range of ex 20 mut'ns, good activity in brain (icRR 48.5%); tox notable for diarrhea & rash, mostly gr 1-2. Real step forward. #LCSM

Nice perspective on continuing IO beyond 2 years versus stopping by H. Jack West, MD. #LCSM

Clinical Decision Making in the Real World—The Perfect as the Enemy of the Good jamanetwork.com/journals/jamao…

🚨Targeted Therapy Increases CURE🚨

Three KEY takeaways:

1️⃣ 50% reduction in death for early stage NSCLC w/ EGFR Mutation
2️⃣ Improved Cure Rates w/ osimertinib
3️⃣ 88% survival at 5 years

🙌🏽🙌🏽🙌🏽

#ADAURA #ASCO23 ASCO
OncoAlert Oncology Brothers

Thank you Ben Solomon for recognizing that while it’s important to celebrate the wins, it’s critical to remember that tolerable is relative and can change over time for those on chronic treatment.
#LCSM #ASCO23 EGFR Resisters

#ASCO23 ADAURAble results!

How it started How it is going
👇 👇

Asking the question #onctwitter & #lcsm family:

Starting tomorrow in clinic, who are we still giving adjuvant chemotherapy to for our pts w/ resected EGFR mutant NSCLC? OncoAlert Oncology Brothers LungCancerRx 🫁💊 Stephen V Liu, MD Sandip Patel MD H. Jack West, MD Nathan A. Pennell MD, PhD, FASCO Charu Aggarwal, MD, MPH, FASCO

Day 3: #ASCO23 #Plenary summary

1. #INDIGO : Vorasidenib in Glioma

2. #PROSPECT : NeoAdj ChemoXRT or FOLFOX —> TME in Rectal Ca

3. #ADAURA : Adj #Osimertinib in NSCLC

4. SWOG Cancer Research Network #S1826 : Nivo or Bv + AVD in advanced cHL

#lcsm #lymsm #gism ASCO #OncTwitter #MedTwitter OncoAlert

A lot of data presented at #ASCO23 . We got a chance to discuss two studies in person:

1. #TROPiCS02 (Sacituzumab) w/ Aditya Bardia, MD: docwirenews.com/post/the-oncol…

2. #ADAURA (Osimertinib) w/ Balazs Halmos: docwirenews.com/post/asco-2023…

#bcsm #lcsm #OncTwitter #MedTwitter DocWire News

🔥🚨OncoAlert #ASCO23 NEGATIVE results of #Keynote789 trial:

Platinum + Pem +/- Pembro for TKI-resistant #EGFR mutant #NSCLC

❌PFS HR 0.8, P=0.0122
mPFS: 5.6 vs 5.5 mths

❌OS HR 0.84, P=0.0362
mOS: 15.9 vs 14.7 mths

After TKI , adding Pembro to chemo DOES NOT improve OS

🔥🚨OncoAlert. Hot off the press.
JUST ISSUED in conjunction with #ASCO23

Rapid #Recommendation Update ASCO #Guidelines on:

“Management of stage III Non-Small Cell #LungCancer #NSCLC .” #LCSM

👇🏼
fal.cn/3yROb